Why the study?
Primary aldosteronism screening cut-offs depend on the assay methods used, requiring performance validation and diagnostic cut-off definition for new chemiluminescent immunoassays on the Lumipulse analyzer.
Does the Lumipulse analyzer accurately measure renin and aldosterone to predict primary aldosteronism in patients with hypertension?
Does the Lumipulse analyzer accurately measure renin and aldosterone to predict primary aldosteronism in patients with hypertension?
The Lumipulse analyzer provides reliable measurements of renin and aldosterone with specific cut-offs (ARR 35 pmol/mIU, PAC 260 pmol/L, 24UA 49 nmol/24h) for diagnosing primary aldosteronism.
Lumipulse cut-offs may aid PA screening in hypertension; leaves open prospective validation before clinical adoption.
OBJECTIVES: Primary aldosteronism (PA) diagnosis is a multistep process that begins with screening based on the plasma aldosterone-to-renin ratio (ARR). As cut-off values depend on the methods used, the aim of this study was 1) to validate the performances of new aldosterone and renin chemiluminescent immuno-assays using the Lumipulse® analyzer (Fujirebio®) and then 2) to define the criteria to distinguish PA patients from those with essential hypertension (EH). METHODS: This monocentric retrospective study included 297 patients admitted to Georges Pompidou European Hospital, France, between January 2021 and December 2022 for the assessment of hypertension etiology. We evaluated analytical performances and compared Lumipulse® results for plasma renin (PRC) and plasma aldosterone (PAC) concentrations (n = 196) as well as 24-hour urine aldosterone excretion (24UA) (n = 201) to the reference methods (PRC: Liaison XL® Diasorin®; PAC and 24UA: LC-MS/MS). Receiver operating characteristic curve analysis was used to define the cut-off values for ARR, PAC, and 24UA to distinguish between PA and EH patients. RESULTS: Analytical characteristics were in accordance with requested performances. Our results showed excellent correlations between Lumipulse® and our reference methods. We propose cut-off values of 35 pmol/mIU as the ARR, 260 pmol/L for PAC, and 49 nmol/24h for 24UA for predicting PA diagnosis. CONCLUSIONS: Lumipulse® (Fujirebio®) is a reliable alternative for measuring PRC, PAC, and 24UA for predicting PA diagnosis with the use of corresponding cut-off values for each criterion.
No takes yet. Share an insight, caveat, or question.
Laney et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: